257 related articles for article (PubMed ID: 29412822)
1. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
[TBL] [Abstract][Full Text] [Related]
2. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Biochem Pharmacol; 2017 Dec; 146():165-173. PubMed ID: 28987595
[TBL] [Abstract][Full Text] [Related]
3. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
6. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
7. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
[TBL] [Abstract][Full Text] [Related]
8. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
9. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
10. Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities.
Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
Eur J Pharmacol; 2020 Jul; 878():173101. PubMed ID: 32320703
[TBL] [Abstract][Full Text] [Related]
11. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
12. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
13. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
14. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
[TBL] [Abstract][Full Text] [Related]
15. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
[TBL] [Abstract][Full Text] [Related]
17. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
18. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis.
McCloskey AG; Miskelly MG; Flatt PR; McKillop AM
Eur J Pharm Sci; 2020 Jan; 142():105104. PubMed ID: 31669388
[TBL] [Abstract][Full Text] [Related]
20. A long-acting, dual-agonist analogue of lamprey GLP-1 shows potent insulinotropic, β-cell protective, and anorexic activities and improves glucose homeostasis in high fat-fed mice.
Graham GV; McCloskey A; Abdel-Wahab YH; Conlon JM; Flatt PR
Mol Cell Endocrinol; 2020 Jan; 499():110584. PubMed ID: 31539596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
